2022-11-25 12:00:00

Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update - Can Fite Biofarma (AME

Logo Benzinga
Benzinga
By Business Wire

Can-Fite BioPharma Ltd. CANF CFBI, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022.

Corporate and Clinical Development Highlights Include:

Complete Clearance of Cancer in a Patient Treated with Namodenoson was Presented at the AASLD Liver Meeting A poster titled Complete Response Induced by Namodenoson, an A3 Adenosine Receptor Agonist, in a Patient with Advanced Hepatocellular Carcinoma was presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in November in Washington, D.C. The findings were published in the October 2022 supplement of HEPATOLOGY, a premier peer-reviewed journal in the field of liver disease. The poster detailed the patient, a 61-year-old woman with hepatocellular carcinoma (HCC), the most common form of liver cancer, and moderate hepatic dysfunction Child-Pugh B (CPB7), who participated in Can-Fite's prior Phase II study. The patient was in the Namodenoson arm of the Phase II study and continued treatment with Namodenoson for 5 years under an open label extension program until the approval of a compassionate use program in Romania in August.

Continue read on benzinga.com

Logo PR Newswire
HealthPress Release2022-11-24 14:30:00
NOIDA, India, Nov. 24, 2022 /PRNewswire/ -- According to a new report published by UnivDatos Markets Insights, the Lung Cancer Therapeutics Market is...

Logo PR Newswire
HealthPress Release2022-11-25 07:41:00
GOTHENBURG, Sweden, Nov. 25, 2022 /PRNewswire/ -- Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT study's...

Logo PR Newswire
HealthPress Release2022-11-24 13:00:00
Adjusted EBITDA loss improved by 20% from previous quarter to $1.3 million compared to $1.7 million in the previous quarter Entered into a $3.5 million...

Logo Benzinga
Business / FinanceBy Pr Newswire2022-11-24 13:00:00
Adjusted EBITDA loss improved by 20% from previous quarter to $1.3 million compared to $1.7 million in the previous quarter Entered into a $3.5 million...

Logo NewsFileCorp
Press Release2022-11-24 13:00:00
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical...

Logo NewsFileCorp
Press Release2022-11-25 00:17:00
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or...

Logo PR Newswire
HealthPress Release2022-11-24 22:00:00
WINNIPEG, MB, Nov. 24, 2022 /CNW/ - Medicure Inc. (" Medicure " or the " Company ") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and...

Logo PR Newswire
HealthPress Release2022-11-24 13:00:00
SHANGHAI, Nov. 24, 2022 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that...

Logo Nasdaq
Business / FinanceBy The Motley Fool2022-11-24 14:45:00
Biotech company Axsome Therapeutics (NASDAQ: AXSM) has had a strong -- although somewhat volatile -- year on the stock market. The company's shares have been...

Logo NewsFileCorp
Press Release2022-11-24 22:21:00
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2022) - SURENANO SCIENCE LTD. ( CSE: SURE ) ( OTCQB: SURNF ) (the " Company " or " SureNano ")...

Logo Benzinga
Business / FinanceBy Business Wire2022-11-25 11:00:00
Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce Spectrum to explore...

Logo PR Newswire
HealthPress Release2022-11-23 13:29:00
FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application (BLA) BioMarin Remains on...

Logo PR Newswire
HealthPress Release2022-11-24 20:15:00
DUBLIN, Nov. 24, 2022 /PRNewswire/ -- The "Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027"...

Logo NewsFileCorp
Press Release2022-11-24 17:02:00
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2022) - wellteq Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF), (the "Company" or "wellteq"),...

Logo Benzinga
Business / FinanceBy Benzinga Insights2022-11-24 14:50:06
According to Benzinga Pro, during Q3, Willdan Group WLDN earned $76 thousand, a 101.76% increase from the preceding quarter. Willdan Group also posted a...

Logo Benzinga
Business / FinanceBy Globe Newswire2022-11-22 14:30:00
Led by a Significant Increase in Duramed, Music City Botanical and Botanical Biotech Brands Adjusted EBITDA Loss Decreased by 25% to $1.5 Million HICKSVILLE,...

Logo Benzinga
Business / FinanceBy Benzinga Insights2022-11-24 14:48:10
According to Benzinga Pro data, during Q3, Oncternal Therapeutics ONCT posted sales of $382 thousand. Earnings were up 5.25%, but Oncternal Therapeutics...

Logo Nasdaq
Business / FinanceBy The Motley Fool2022-11-24 14:15:00
As 2022 draws to a close, the cannabis sector is once again heating up. With marijuana regulations on the ballot, major players in the industry making big...

Logo PR Newswire
HealthPress Release2022-11-24 20:30:00
DUBLIN, Nov. 24, 2022 /PRNewswire/ -- The "Cancer Gene Therapy Market Size, Share & Trends Analysis Report by Therapy (Oncolytic Virotherapy, Gene...

Logo Daily Mail
HealthBy Xantha Leatham2022-11-23 16:00:46
Thousands of kidney patients could potentially benefit from a new breakthrough. Researchers have discovered an existing lung cancer drug may be effective...